China IVD market: Driving the next leg of growth

The outlook on China’s in vitro diagnostics (IVD) market remains solid, even as overall market growth slows as a result of policy impact. EIU Healthcare’s IVD Gateway predicts the strong growth trend in China to continue over the next few years – averaging ~10% annually from 2018 to 2023.

To be positioned for market success in the coming years, IVD companies will need to adjust existing growth strategies to new realities and dynamics in China’s IVD market.

In this whitepaper “China IVD Market 2019: Driving the Next Leg of Growth”, EIU Healthcare examines how key reforms and regulatory changes have shifted local market dynamics and the opportunities emerging from the changes. In particular, how the Class 2 hospital market has emerged as a key customer segment that will drive the next phase of growth for IVD companies.

Download the whitepaper to find out:

• Overall market size in 2018 and growth outlook (2018-2023) for China’s IVD market  

• Overall trend in four key IVD market segments of centralised diagnostics (CDx), molecular diagnostics (MDx), point-of-care (POC) diagnostics and tissue diagnostics (TDx), and the top 3 most promising test areas in each

• The extent of the impact of policies and regulations in relation to Made in China 2025 initiative on the competitive landscape, including how fast are key domestic players such as Mindray, BGI, Snibe and AmoyDx growing in China’s IVD market; how much reach domestic players have in the Class 2 hospital segment

• The extent of the impact of provincial-level price controls on IVD business growth and performance 

• How healthcare reforms guided by the Healthy China 2030 vision have created new growth avenues with lower-tier hospitals

• How and where to capture profitability in the Class 2 hospital segment

For more data and insights on the surgical market, find out more about EIU Healthcare’s IVD Gateway.